In this video, Swaminathan Iyer, MD, University of Texas MD Anderson Cancer Center, Houston, TX, briefly explains the CRISPR-CAS9 gene editing process behind CTX130 and how this gene editing process aims to improve the efficacy of this novel CAR-T agent. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

свернуть